Menu
← Oncology Approval Tracker
FDA DECISION ·
Braftovi + Mektovi
encorafenib + binimetinib · Array BioPharma / Pfizer
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with metastatic NSCLC and BRAF V600E confirmed by an FDA-approved test.
LAMPGEN ANALYSIS
Why it matters
The combination extended dual BRAF and MEK inhibition into a biomarker-selected lung cancer setting.
What research teams should watch
Check the exact BRAF variant and document baseline organ assessments appropriate to the two-drug regimen.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
Biomarker-selected advanced NSCLCPRIMARY RECORDS